Internal Medicine, Hematology & Oncology · Peabody, MA
NPI
1598711160
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1 Essex Center Dr
Peabody, MA, 01960
Phone (978) 538-4330
Groups this clinician bills Medicare through
Medicare paid, 2024
$102K
1,315 services
Medicare patients, 2024
366
Average age 76
Drug cost, 2024
$3.5M
953 prescriptions
Company payments, 2025
$147K
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Karl J D'Silva was code 99215 (office e&m - established), 621 times for 265 patients. In total Karl J D'Silva billed 1,315 services in 15 codes, and Medicare paid $102K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-09-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 621 | 265 | $107.53 | $67K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 365 | 206 | $13.32 | $4,861 |
| 99214 Office E&M - Established | Facility | 94 | 81 | $64.86 | $6,097 |
| 99233 Hospital E&M - Subsequent | Facility | 82 | 27 | $101.19 | $8,297 |
| 99205 Office E&M - New | Facility | 52 | 52 | $127.82 | $6,647 |
| 99239 Hospital Discharge Management | Facility | 20 | 19 | $98.51 | $1,970 |
| 99223 Hospital E&M - Initial | Facility | 19 | 19 | $147.72 | $2,807 |
| 99213 Office E&M - Established | Facility | 12 | 12 | $53.37 | $640 |
| 99214 Office E&M - Established | Office | 12 | 12 | $91.38 | $1,097 |
By year: 2022 $92K for 952 services; 2023 $84K for 847 services; 2024 $102K for 1,315 services.
Medicare prescription drug claims, 2024
In 2024, the drug Karl J D'Silva prescribed most often to Medicare patients was Prochlorperazine Maleate, with 73 prescriptions and refills. In total Karl J D'Silva wrote 953 Medicare prescriptions that cost $3.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prochlorperazine Maleate Generic | 73 | 73 | 42 | $893 |
| Abiraterone Acetate Generic | 71 | 75 | Under 11 | $102K |
| Oxycodone Hcl Generic | 66 | 66 | 19 | $1,173 |
| Prednisone Generic | 54 | 105 | 27 | $199 |
| Dexamethasone Generic | 53 | 57 | 28 | $633 |
| Orgovyx Relugolix | 47 | 47 | Under 11 | $122K |
| Nubeqa Darolutamide | 46 | 46 | Under 11 | $599K |
| Xtandi Enzalutamide | 43 | 43 | Under 11 | $580K |
| Ondansetron Hcl Generic | 41 | 41 | 24 | $197 |
| Lorazepam Generic | 34 | 35 | 11 | $131 |
| Olanzapine Generic | 32 | 32 | 13 | $221 |
| Brukinsa Zanubrutinib | 28 | 28 | Under 11 | $408K |
| Klor-Con M20 Potassium Chloride | 23 | 47 | Under 11 | $276 |
| Eliquis Apixaban | 21 | 25 | Under 11 | $15K |
| Tagrisso Osimertinib Mesylate | 18 | 18 | Under 11 | $314K |
Brand drugs: 279 claims; generic drugs: 674 claims; opioid claims: 96.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Karl J D'Silva $147K ($147K in general payments such as food, travel and fees) from 24 companies. The largest payer was Astellas Pharma US Inc with $58K.
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc 4503.T | 57 | $58K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 48 | $35K |
| AstraZeneca Pharmaceuticals LP AZN | 23 | $20K |
| Jazz Pharmaceuticals Inc. JAZZ | 12 | $14K |
| Janssen Biotech, Inc. JNJ | 30 | $7,527 |
| Pfizer Inc. PFE | 6 | $5,685 |
| SpringWorks Therapeutics, Inc. | 8 | $2,473 |
| Abbvie Inc. ABBV | 1 | $2,100 |
| Cipla USA Inc. CIPLA.NS | 2 | $1,110 |
| Incyte Corporation INCY | 1 | $1,100 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.